In Vitro Activities of Ravuconazole (BMS-207147) against 541 Clinical Isolates of Cryptococcus neoformans

The in vitro activities of the new triazole, ravuconazole (BMS-207147), were compared to those of fluconazole and itraconazole against 541 clinical isolates of Cryptococcus neoformans. Isolates were obtained from cerebrospinal fluid (396), blood (116), and miscellaneous clinical specimens (29). Over...

Descrición completa

Detalles Bibliográficos

Publicado en:	Antimicrob Agents Chemother
Principais autores:	Yamazumi, T., Pfaller, M. A., Messer, S. A., Houston, A., Hollis, R. J., Jones, R. N.
Formato:	Artigo
Idioma:	Inglês
Publicado:	American Society for Microbiology (ASM) 2000
Assuntos:	Susceptibility
Acceso en liña:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC90171/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/10991880/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.44.10.2883-2886.2000
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!